Pathogenesis of coronary artery disease: Focus on genetic risk factors and identification of genetic variants

Application of Clinical Genetics

Volumn 7, Issue , 2014, Pages 15-32

  Sayols Baixeras, Sergi ^a   Lluís Ganella, Carla ^a   Lucas, Gavin ^a   Elosua, Roberto ^a  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

Coronary artery disease; Genetic risk factors; Genetic variants; Pathogenesis

Indexed keywords

CLOPIDOGREL;

9P21 GENE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CYP2C19 GENE; DRUG TARGETING; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCUS; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC VARIABILITY; GENOME ANALYSIS; HERITABILITY; HIGH RISK POPULATION; HUMAN; OBESITY; PATHOGENESIS; PCSK9 GENE; PHARMACOGENOMICS; PHENOTYPE; REVIEW;

EID: 84892561711     PISSN: None     EISSN: 1178704X     Source Type: Journal    
DOI: 10.2147/TACG.S35301     Document Type: Review

References (126)

1. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197-2223.
2. Lluis-Ganella C. Genetic Factors Associated with Coronary Heart Disease and Analysis of their Predictive Capacity. Barcelona, Spain: Universitat Pompeu Fabra; 2012.
3. Mecchia D, Lavezzi AM, Mauri M, Matturri L. Feto-placental atherosclerotic lesions in intrauterine fetal demise: role of parental cigarette smoking. Open Cardiovasc Med J. 2009;3:51-56.
4. Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet. 2004;5:189-218.
5. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104:503-516.
6. Sanz J, Moreno P, Fuster V. The year in atherothrombosis. J Am Coll Cardiol. 2013;24;62:1131-1143.
7. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science. 2013;339:166-172.
8. Sakakura K, Nakano M, Otsuka F, Ladich E, Kolodgie FD, Virmani R. Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ. 2013;22:399-411.
9. Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E. Monocytes in coronary artery disease and atherosclerosis: where are we now? J Am Coll Cardiol. 2013;62:1541-1551.
10. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325.
11. Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol. August 7, 2013. [Epub ahead of print.]
12. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045-2051.
13. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 2010;10:36-46.
14. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010;30: 1282-1292.
15. Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol. 2007;49:2073-2080.
16. Visscher PM, Hill WG, Wray NR. Heritability in the genomics era-concepts and misconceptions. Nat Rev Genet. 2008;9:255-266.
17. Elosua R, Lluis-Ganella C, Lucas G. Research into the genetic component of heart disease: from linkage studies to genome-wide genotyping. Rev Esp Cardiol Suppl. 2009;9 Suppl:24B-38B.
18. Peden JF, Farrall M. Thirty-five common variants for coronary artery disease: the fruits of much collaborative labour. Hum Mol Genet. 2011;20:R198-R205.
19. Chial H. Mendelian genetics: patterns of inheritance and single-gene disorders. Nature Education. 2008;1(1). Available from: http://www.nature.com/scitable/topicpage/mendelian-genetics-patterns-of-inheritance-and-single-966. Accessed November 4, 2013.
20. Lobo I. Multifactorial inheritance and genetic disease. Nature Education 2008;1(1). Available from: http://www.nature.com/scitable/topicpage/multifactorial-inheritance-and-genetic-disease-919. Accessed November 4, 2013.
21. Deloukas P, Kanoni S, Willenborg C, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45:25-33.
22. Dawn TM, Barrett JH. Genetic linkage studies. Lancet. 2005;366: 1036-1044.
23. Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. Cell. 2012;148:1242-1257.
24. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension. 2005;45:907-913.
25. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233-239.
26. Wang L, Fan C, Topol SE, Topol EJ, Wang Q. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science. 2003;302:1578-1581.
27. Varret M, Rabes JP, Saint-Jore B, et al. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am J Hum Genet. 1999;64:1378-1387.
28. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273:1516-1517.
29. Zhu M, Zhao S. Candidate gene identification approach: progress and challenges. Int J Biol Sci. 2007;3:420-427.
30. Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet. 2002;3:391-397.
31. Attia J, Ioannidis JP, Thakkinstian A, et al. How to use an article about genetic association. C: What are the results and will they help me in caring for my patients? JAMA. 2009;301:304-308.
32. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003;33:177-182.
33. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Hum Genet. 2012;90:7-24.
34. The International HapMap Consortium. A haplotype map of the human genome. Nature. 2005;437:1299-1320.
35. US Department of Energy Human Genome Project. Available from: http://www.ornl.gov/hgmis. Accessed November 4, 2013.
36. Arking DE, Chakravarti A. Understanding cardiovascular disease through the lens of genome-wide association studies. Trends Genet. 2009;25:387-394.
37. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559-575.
38. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an Rlibrary for genome-wide association analysis. Bioinformatics. 2007;23:1294-1296.
39. Roberts R, Stewart AF. Genes and coronary artery disease: where are we? J Am Coll Cardiol. 2012;60:1715-1721.
40. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747-753.
41. Hindorff LA, Junkins HA, Mehta JP, Manolio TA. A catalog of published genome-wide association studies. Available from: http://www.genome.gov/gwastudies. Accessed November 4, 2013.
42. Marian AJ. Challenges in medical applications of whole exome/genome sequencing discoveries. Trends Cardiovasc Med. 2012;22:219-223.
43. Almasy L. The role of phenotype in gene discovery in the whole genome sequencing era. Hum Genet. 2012;131:1533-1540.
44. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491-1493.
45. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488-1491.
46. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000shared controls. Nature. 2007;447:661-678.
47. Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42:105-116.
48. Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103-109.
49. Heid IM, Jackson AU, Randall JC, et al. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet. 2010;42:949-960.
50. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42:937-948.
51. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466: 707-713.
52. Voight BF, Scott LJ, Steinthorsdottir V, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42:579-589.
53. Wain LV, Verwoert GC, O'Reilly PF, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet. 2011;43:1005-1011.
54. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156.
55. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53:2515-2524.
56. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9in primary hypercholesterolemia. N Engl J Med. 2012;367:1891-1900.
57. McPherson R. Chromosome 9p21.3 locus for coronary artery disease: how little we know. J Am Coll Cardiol. 2013;62(15):1382-1383.
58. Aguero F, Degano IR, Subirana I, et al. Impact of a partial smoke-free legislation on myocardial infarction incidence, mortality and case-fatality in a population-based registry: the REGICOR study. PLoS One. 2013;8:e53722.
59. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Rev Esp Cardiol. 2012;65:66-241.
60. Expert Panelon Detection, Evaluation, and Treatment of High Blood Cholesterolin Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
61. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
62. Marrugat J, Vila J, Baena-Diez JM, et al. Relative validity of the 10-year cardiovascular risk estimate in a population cohort of the REGICOR study. Rev Esp Cardiol. 2011;64:385-394.
63. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation. 2011;123: 551-565.
64. Candore G, Balistreri CR, Caruso M, et al. Pharmacogenomics: a tool to prevent and cure coronary heart disease. Curr Pharm Des. 2007;13:3726-3734.
65. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-549.
66. Marin F, Gonzalez-Conejero R, Capranzano P, Bass TA, Roldan V, Angiolillo DJ. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol. 2009;54:1041-1057.
67. Motulsky AG. Drug reactions enzymes, and biochemical genetics. J Am Med Assoc. 1957;165:835-837.
68. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet. 2000;355:1358-1361.
69. Voora D, Ginsburg GS. Clinical application of cardiovascular pharmacogenetics. J Am Coll Cardiol. 2012;60:9-20.
70. Verschuren JJ, Trompet S, Wessels JA, et al. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Eur Heart J. 2012;33:165-175.
71. Simon JA, Lin F, Hulley SB, et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol. 2006;97:843-850.
72. Iakoubova OA, Sabatine MS, Rowland CM, et al. Polymorphism in KIF6gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22study. J Am Coll Cardiol. 2008;51: 449-455.
73. Iakoubova OA, Tong CH, Rowland CM, et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008;51:435-443.
74. Hopewell JC, Parish S, Clarke R, et al. No impact of KIF6genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. J Am Coll Cardiol. 2011;57:2000-2007.
75. Ridker PM, MacFadyen JG, Glynn RJ, Chasman DI. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention. Circ Cardiovasc Genet. 2011;4:312-317.
76. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008;359:789-799.
77. Johnson JA, Cavallari LH, Beitelshees AL, Lewis JP, Shuldiner AR, Roden DM. Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther. 2011;90:519-531.
78. Zabalza M, Subirana I, Sala J, et al. Meta-analyses of the association between cytochrome CYP2C19 loss-and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart. 2012;98:100-108.
79. US Department of Health and Human Services. Information on clopidogrel bisulfate. 27-10-2007. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm190836.htm. Accessed November 4, 2013.
80. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010;122:537-557.
81. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ. 2011;343:d4588.
82. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011;306:2704-2714.
83. Maouche S, Schunkert H. Strategies beyond genome-wide association studies for atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:170-181.
84. Evangelou E, Ioannidis JP. Meta-analysis methods for genome-wide association studies and beyond. Nat Rev Genet. 2013;14:379-389.
85. Prins BP, Lagou V, Asselbergs FW, Snieder H, Fu J. Genetics of coronary artery disease: genome-wide association studies and beyond. Atherosclerosis. 2012;225:1-10.
86. Manolio TA. Bringing genome-wide association findings into clinical use. Nat Rev Genet. 2013;14:549-558.
87. Chatterjee N, Wheeler B, Sampson J, Hartge P, Chanock SJ, Park JH. Projecting the performance of risk prediction based on polygenic analyses of genome-wide association studies. Nat Genet. 2013;45: 400-403.
88. Hudson KL, Holohan MK, Collins FS. Keeping pace with the times-the Genetic Information Nondiscrimination Act of 2008. N Engl J Med. 2008;358:2661-2663.
89. Nora JJ, Lortscher RH, Spangler RD, Nora AH, Kimberling WJ. Genetic-epidemiologic study of early-onset ischemic heart disease. Circulation. 1980;61:503-508.
90. Zdravkovic S, Wienke A, Pedersen NL, Marenberg ME, Yashin AI, de Faire U. Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins. J Intern Med. 2002;252: 247-254.
91. Wienke A, Holm NV, Skytthe A, Yashin AI. The heritability of mortality due to heart diseases: a correlated frailty model applied to Danish twins. Twin Res. 2001;4:266-274.
92. Peyser PA, Bielak LF, Chu JS, et al. Heritability of coronary artery calcium quantity measured by electron beam computed tomography in asymptomatic adults. Circulation. 2002;106:304-308.
93. Xiang AH, Azen SP, Buchanan TA, et al. Heritability of subclinical atherosclerosis in Latino families ascertained through a hypertensive parent. Arterioscler Thromb Vasc Biol. 2002;22:843-848.
94. Fox CS, Polak JF, Chazaro I, et al. Genetic and environmental contributions to atherosclerosis phenotypes in men and women: heritability of carotid intima-media thickness in the Framingham Heart Study. Stroke. 2003;34:397-401.
95. Swan L, Birnie DH, Inglis G, Connell JM, Hillis WS. The determination of carotid intima medial thickness in adults-a population-based twin study. Atherosclerosis. 2003;166:137-141.
96. North KE, MacCluer JW, Devereux RB, et al. Heritability of carotid artery structure and function: the Strong Heart Family Study. Arterioscler Thromb Vasc Biol. 2002;22:1698-1703.
97. Hunt KJ, Duggirala R, Goring HH, et al. Genetic basis of variation in carotid artery plaque in the San Antonio Family Heart Study. Stroke. 2002;33:2775-2780.
98. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston, MA: Little, Brown, and Company; 1987.
99. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med. 2002;4:45-61.
100. Hulley S, Cummings SR, Browner WS. Designing Clinical Research: An Epidemiologic Approach. Baltimore, MD: Lippincott, Williams and Wilkins; 2001.
101. Khoury MJ, Beaty T, Cohen B. Fundamentals of Genetic Epidemiology. New York, NY: Oxford University Press; 1993.
102. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology. 2008;19:640-648.
103. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2:e124.
104. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA. 2008;299:1335-1344.
105. Davies RW, Dandona S, Stewart AF, et al. Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet. 2010;3:468-474.
106. Anderson JL, Horne BD, Camp NJ, et al. Joint effects of common genetic variants from multiple genes and pathways on the risk of premature coronary artery disease. Am Heart J. 2010;160:250-256.
107. Qi L, Ma J, Qi Q, Hartiala J, Allayee H, Campos H. Genetic risk score and risk of myocardial infarction in Hispanics. Circulation. 2011;123: 374-380.
108. Qi L, Parast L, Cai T, et al. Genetic susceptibility to coronary heart disease in type 2 diabetes: 3independent studies. J Am Coll Cardiol. 2011;58:2675-2682.
109. Lv X, Zhang Y, Rao S, et al. Joint effects of genetic variants in multiple loci on the risk of coronary artery disease in Chinese Han subjects. Circ J. 2012;76:1987-1992.
110. Patel RS, Sun YV, Hartiala J, et al. Association of a genetic risk score with prevalent and incident myocardial infarction in subjects undergoing coronary angiography. Circ Cardiovasc Genet. 2012;5: 441-449.
111. Hughes MF, Saarela O, Stritzke J, et al. Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts. PLoS One. 2012;7:e40922.
112. Vaarhorst AA, Lu Y, Heijmans BT, et al. Literature-based genetic risk scores for coronary heart disease: the Cardiovascular Registry Maastricht (CAREMA) prospective cohort study. Circ Cardiovasc Genet. 2012;5:202-209.
113. Morrison AC, Bare LA, Chambless LE, et al. Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities study. Am J Epidemiol. 2007;166:28-35.
114. Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008;358:1240-1249.
115. Talmud PJ, Cooper JA, Palmen J, et al. Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin Chem. 2008;54:467-474.
116. Brautbar A, Ballantyne CM, Lawson K, et al. Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study. Circ Cardiovasc Genet. 2009;2:279-285.
117. Paynter NP, Chasman DI, Buring JE, Shiffman D, Cook NR, Ridker PM. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med. 2009;150:65-72.
118. Paynter NP, Chasman DI, Pare G, et al. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA. 2010;303:631-637.
119. Ripatti S, Tikkanen E, Orho-Melander M, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376:1393-1400.
120. Shiffman D, O'Meara ES, Rowland CM, et al. The contribution of a 9p21.3 variant, a KIF6 variant, and C-reactive protein to predicting risk of myocardial infarction in a prospective study. BMC Cardiovasc Disord. 2011;11:10.
121. Thanassoulis G, Peloso GM, Pencina MJ, et al. A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium-the Framingham Heart Study. Circ Cardiovasc Genet. 2012;5:113-121.
122. Lluis-Ganella C, Subirana I, Lucas G, et al. Assessment of the value of a genetic risk score in improving the estimation of coronary risk. Atherosclerosis. 2012;222:456-463.
123. Gransbo K, Almgren P, Sjogren M, et al. Chromosome 9p21genetic variation explains 13% of cardiovascular disease incidence but does not improve risk prediction. J Intern Med. 2013;274:233-240.
124. Isaacs A, Willems SM, Bos D, et al. Risk scores of common genetic variants for lipid levels influence atherosclerosis and incident coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33:2233-2239.
125. Ganna A, Magnusson PK, Pedersen NL, et al. Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol. 2013;33:2267-2272.
126. Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33:2261-2266.